Melatonin Milpharm (Melatonin)

Melatonin Milpharm acts on melatonin receptors to address sleep‑related conditions.

• Insomnia: facilitates sleep onset and improves sleep continuity in individuals with difficulty falling asleep.
• Circadian rhythm sleep disorders: helps realign disrupted internal clocks, such as delayed sleep phase disorder, to promote a more normal sleep‑wake pattern.
• Jet lag: reduces the time needed to adjust to new time zones by advancing or delaying the circadian rhythm.

• Melatonin binds to MT1 and MT2 receptors in the suprachiasmatic nucleus, mimicking endogenous melatonin. This interaction modulates the circadian clock, lowers core body temperature, and promotes the physiological processes that initiate sleep, thereby facilitating sleep onset and maintenance.

Melatonin Milpharm may cause a range of adverse reactions.

Common Side Effects

• Drowsiness or daytime sleepiness
• Headache
• Dizziness
• Nausea or mild gastrointestinal discomfort
• Vivid dreams or nightmares
• Mild fatigue

Serious or Rare Side Effects

• Allergic reactions such as rash, itching, or swelling
• Severe hypersensitivity including anaphylaxis
• Mood alterations, including depression or agitation
• Hallucinations or psychotic symptoms (rare)
• Respiratory depression (very rare)
• Significant blood pressure changes (rare)

When using Melatonin Milpharm, consider the following precautions.

• Assess sleep pattern: evaluate underlying causes before initiating therapy.
• Avoid driving or operating machinery: potential residual drowsiness may impair performance.
• Use with caution in hepatic impairment: melatonin is metabolized by the liver.
• Do not combine with other sedatives without medical advice: risk of additive CNS depression.
• Pregnancy and breastfeeding: consult a healthcare professional before use.
• Store at room temperature: keep in the original pack, protect from moisture and light.

Melatonin can interact with several medication classes.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): may increase bleeding risk.
• Immunosuppressants (e.g., cyclosporine): potential reduction in immunosuppressive effect.
• CYP1A2 inhibitors (e.g., fluvoxamine): may raise melatonin plasma concentrations.

Moderate Interactions (Monitor Closely)

• Central nervous system depressants (e.g., benzodiazepines, antihistamines): additive sedation.
• Antidepressants (e.g., SSRIs, MAOIs): possible serotonin syndrome.
• Oral contraceptives: may alter melatonin metabolism and efficacy.